Ocugen's Phase 1/2 Study of OCU410 Approved for Continuation by DSMB

TipRanks06:45 ET

Express News | Ocugen Inc - Dsmb Approves Continuation of Ocu410 Armada Phase 1/2 Study

Reuters06:38 ET

Express News | Ocugen Inc: Ocu410 Has a Very Favorable Safety and Tolerability Profile

Reuters06:38 ET

Express News | Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of Ocu410 Armada Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Reuters06:38 ET

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen00:00 ET

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

OcugenDec 11 00:00 ET